Tandem Therapeutics joins Wyss Zurich Translational Center to accelerate progress in fibrosis treatment

15.04.2024 15:50, Rita Longobardi

Venture Kick and Venture Leaders alumnus Tandem Therapeutics has been accepted into the Wyss Zurich Translational Center as Project Tandem. With the support of this accelerator program — providing access to world-class infrastructure and experts, as well as financial backing — Tandem Therapeutics will advance translational R&D efforts aimed at developing novel peptide drug conjugates to precisely target and treat fibrosis-driven diseases.

Fibrosis represents a significant unmet medical challenge, contributing to over 45% of deaths in the developed world. Progressive fibrosis leads to the disruption of organ function and represents a significant cause of morbidity and mortality globally. Tandem Therapeutics aims to go beyond conventional cell targeting by harnessing the unique "mechanical fingerprint" of the extracellular matrix, known to drive disease progression.

Leveraging successful proof-of-concept data and with the support from Wyss Zurich, Tandem Therapeutics aims to develop lead candidates to treat progressive lung fibrosis, a devastatingly fatal disease with no available cure.

Tandem Therapeutics won Venture Kick and participated in Venture Leaders Biotech in 2023.

“Venture Leaders is a fantastic program for Swiss startups to understand entry and growth in the US market. The highly action-packed roadshow helped us sharpen our value proposition, bring in broad perspectives on the opportunities and a peer-network worth it’s value in gold. It should be a high priority for every biotech entrepreneur’s journey!” commented Mamta Chabria, CEO and Co-Founder of Tandem Therapeutics.

Tandem Therapeutics' Co-Founders: Prof. Dr. Viola Vogel, Dr. Mamta Chabria, and Dr. Martin Behe